Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
Published Time:
2024-11-18 18:09
Source:
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
Hidden Unicorns—a new concept—represent high-potential enterprises critical to sci-tech cultivation. The report, the fourth of its kind, uses the Global Unicorn 500 database and Hidden Unicorn evaluation criteria (requiring original/disruptive technologies and irreplicable business models). Through AI-augmented analysis, the top 500 Hidden Unicorns in China were selected.
Since its founding, Jiangsu Vcare has focused on innovative drugs and advanced therapies, evolving into a dual-core enterprise (innovative drug R&D + full-chain CRO/CDMO services). It currently has5 clinical-stage Class I innovative drug projectsand10+ preclinical projects, with a pipeline centered on Vicagrel covering cardiovascular, oncology, and autoimmune diseases. Its CRO/CDMO arm serves 300+ global clients, operating the 130-mu (approx. 8.67 hectares) CDMO facility—Hubei Tianshu Pharmaceutical Co., Ltd.in a provincial chemical park—providing integrated services from advanced intermediates to APIs, and from CMC to clinical CRO and registration.
This recognition affirms Jiangsu Vcare’s "hardcore" R&D strength and future potential. The company will implement a "new quality productivity" strategy, advancing its dual-core model (innovative drugs + full-chain CRO/CDMO) to become a top-tier global pharmaceutical group.
Related News
08
2024
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) reported positive results from its Phase II clinical trial of VC005 tablets, a second-generation selective JAK1 inhibitor, for the treatment of ankylosing spondylitis (AS).
View Details
02
2024
/
07
Jiangsu Vcare and Geneseeq Form Strategic Partnership for NTRK Companion Diagnostics
On July 2, 2024, Jiangsu Vcare and Geneseeq signed a strategic cooperation agreement in Nanjing’s Jiangbei New District. The collaboration will focus on the joint development and future commercialization of a companion diagnostic kit for the NTRK inhibitor VC004.
View Details
07
2024
/
06
Jiangsu Vcare Unveils Phase I Clinical Trial Results of TRK Inhibitor VC004 at 2024 ASCO
On June 2, 2024，Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) unveiled the Phase I clinical trial results of its self-developed next-generation TRK inhibitor, VC004, for the treatment of locally advanced/metastatic solid tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
View Details
28
2024
/
04
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of participants enrollment in its Phase I clinical trial for VC005, a second-generation selective JAK1 inhibitor developed as a topical gel formulation for the treatment of mild-to-moderate atopic dermatitis (AD). The trial included four cohorts of healthy volunteers and three cohorts of patients. The blinded analysis demonstrated promising efficacy and safety profiles for the drug.
View Details
20
2024
/
03
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of Phase II clinical enrollment for its self-developed second-generation selective JAK1 inhibitor VC005 tablets in the treatment of moderate-to-severe atopic dermatitis (AD). Preliminary blinded analysis from the clinical trial demonstrated promising efficacy and safety profiles for VC005.
View Details
07
2024
/
02
I. Important Progress in Innovative Drug R&D ① Submitted NDA to US FDA for anti-platelet drug Vicagrel: If approved, it may benefit ~27.6M US patients with coronary heart disease/stroke. ② Completed 1st patient enrollment in China’s Phase II trial for anti-resistant TRK inhibitor VC004: Phase I data showed ORR of 80%-90% in NTRK fusion+ solid tumors and DOR up to 24 months. ③ Completed Phase II enrollment for 2nd-gen selective JAK1 inhibitor VC005 in ankylosing spondylitis: Preliminary blinded analysis showed favorable efficacy/safety. Additionally: VC004 gel approved for clinical trials; VC005 gel initiated China Phase I for atopic dermatitis; Multiple preclinical projects advanced in cardio-cerebrovascular, oncology, and autoimmune fields.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn